AURA (Aura Biosciences) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 06, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Aura Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Aura Biosciences's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Aura Biosciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Aura Biosciences Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Boston, MA, USA, 02135

Website

https://www.aurabiosciences.com

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Executives

Janet Jill Hopkins	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
De Los Pinos Elisabet	director, officer: Chief Executive Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Julie B Feder	officer: Chief Financial Officer	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Matrix Capital Management Company, Lp	10 percent owner	1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cadmus Rich	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De	officer: Chief Operating Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp	10 percent owner	C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi	director	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel	10 percent owner	C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar	director	C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730